Our Work

This study assesses how third-party digital health apps (those not specifically tied to a diabetes device) impact glycemic control, mental well-being, and BMI. ‍

This study explores how activity monitoring mobile apps and software impact overall health outcomes in PWT2, focusing on both physical and mental well-being.

dQ&A presented three research abstracts at ATTD 2025, an academic and professional conference of innovation and advancement in diabetes devices. 

People with Type 1 diabetes (PWT1) in Europe (EU) and the United States (USA) generally have similar access to diabetes technologies. So how do their health outcomes compare? dQ&A’s work shows that even with similar treatment plans, differing regional factors influencing diabetes management — such as obesity levels and the cost and accessibility of healthcare — potentially affect patient wellness.

Unreliable respondents are the scourge of consumer panels. Our data shows that cheaters and bots typically represent the majority of commercially available diabetes patient sample. We routinely see them in healthcare provider sample as well.

Our Qual team has conducted thousands of interviews with patients and medical professionals. We map patient journeys, test and refine diabetes devices in development, assess communication effectiveness and uncover prescribing drivers and barriers.

Our latest Diabetes Drug Insights study follows a group of more than n=3,000 people with type 2 diabetes in the USA from 2018 to 2024.

The latest data in our current survey highlights geographical differences in the comorbidities experienced by people with diabetes along with satisfaction with their glucose control.